S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NYSEAMERICAN:TRXC

TransEnterix Stock Forecast, Price & News

$2.07
+0.08 (+4.02 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$1.90
Now: $2.07
$2.29
50-Day Range
$0.41
MA: $0.53
$1.17
52-Week Range
$0.28
Now: $2.07
$2.29
Volume1.49 million shs
Average Volume28.15 million shs
Market Capitalization$206.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
TransEnterix logo

MarketRank

Overall MarketRank

0.71 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.53 million
Cash Flow$1.48 per share
Book Value$2.68 per share

Profitability

Net Income$-154,200,000.00
Net Margins-2,149.15%

Miscellaneous

Market Cap$206.81 million
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable
$2.07
+0.08 (+4.02 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Is TransEnterix a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TransEnterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRXC, but not buy additional shares or sell existing shares.
View analyst ratings for TransEnterix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than TransEnterix?

Wall Street analysts have given TransEnterix a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TransEnterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for TransEnterix
.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings data on Thursday, November, 5th. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.11. The medical instruments supplier had revenue of $0.81 million for the quarter, compared to analysts' expectations of $0.73 million. TransEnterix had a negative net margin of 2,149.15% and a negative return on equity of 83.74%.
View TransEnterix's earnings history
.

What guidance has TransEnterix issued on next quarter's earnings?

TransEnterix updated its fourth quarter 2020 Pre-Market earnings guidance on Wednesday, January, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.1-1.1 million, compared to the consensus revenue estimate of $1.04 million.

Are investors shorting TransEnterix?

TransEnterix saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 6,950,000 shares, an increase of 45.7% from the December 15th total of 4,770,000 shares. Based on an average trading volume of 3,500,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 7.6% of the company's stock are short sold.
View TransEnterix's Short Interest
.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), OPKO Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Enterprise Bank & Trust Co (0.12%). Company insiders that own TransEnterix stock include Andrea Biffi, David Bruce Milne, Joseph P Slattery and William N Starling, Jr.
View institutional ownership trends for TransEnterix
.

Which major investors are buying TransEnterix stock?

TRXC stock was bought by a variety of institutional investors in the last quarter, including Enterprise Bank & Trust Co.
View insider buying and selling activity for TransEnterix
or or view top insider-buying stocks.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $2.07.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $206.81 million and generates $8.53 million in revenue each year. The medical instruments supplier earns $-154,200,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.